Literature DB >> 32669335

A Rare Mutation in an Infant-Derived HIV-1 Envelope Glycoprotein Alters Interprotomer Stability and Susceptibility to Broadly Neutralizing Antibodies Targeting the Trimer Apex.

Nitesh Mishra1, Shaifali Sharma1, Ayushman Dobhal1, Sanjeev Kumar1, Himanshi Chawla1, Ravinder Singh2, Bimal Kumar Das2, Sushil Kumar Kabra3, Rakesh Lodha3, Kalpana Luthra4.   

Abstract

The envelope glycoprotein (Env) of human immunodeficiency virus type 1 (HIV-1) is the sole target of broadly neutralizing antibodies (bnAbs). Several mechanisms, such as the acquisition of mutations, variability of the loop length, and alterations in the glycan pattern, are employed by the virus to shield neutralizing epitopes on Env to sustain survival and infectivity within the host. The identification of mutations that lead to viral evasion of the host immune response is essential for the optimization and engineering of Env-based trimeric immunogens. Here, we report a rare leucine-to-phenylalanine escape mutation (L184F) at the base of hypervariable loop 2 (population frequency of 0.0045%) in a 9-month-old perinatally HIV-1-infected infant broad neutralizer. The L184F mutation altered the trimer conformation by modulating intramolecular interactions stabilizing the trimer apex and led to viral escape from autologous plasma bnAbs and known N160 glycan-targeted bnAbs. The L184F amino acid change led to the acquisition of a relatively open trimeric conformation, often associated with tier 1 HIV-1 isolates and increased susceptibility to neutralization by polyclonal plasma antibodies of weak neutralizers. While there was no impact of the L184F mutation on free virus transmission, a reduction in cell-to-cell transmission was observed. In conclusion, we report a naturally selected viral mutation, L184F, that influenced a change in the conformation of the Env trimer apex as a mechanism of escape from contemporaneous plasma V2 apex-targeted nAbs. Further studies should be undertaken to define viral mutations acquired during natural infection, to escape selection pressure exerted by bnAbs, to inform vaccine design and bnAb-based therapeutic strategies.IMPORTANCE The design of HIV-1 envelope-based immunogens capable of eliciting broadly neutralizing antibodies (bnAbs) is currently under active research. Some of the most potent bnAbs target the quaternary epitope at the V2 apex of the HIV-1 Env trimer. By studying naturally circulating viruses from a perinatally HIV-1-infected infant with plasma neutralizing antibodies targeted to the V2 apex, we identified a rare leucine-to-phenylalanine substitution, in two out of six functional viral clones, that destabilized the trimer apex. This single-amino-acid alteration impaired the interprotomeric interactions that stabilize the trimer apex, resulting in an open trimer conformation and escape from broadly neutralizing autologous plasma antibodies and known V2 apex-directed bnAbs, thereby favoring viral evasion of the early bnAb response of the infected host. Defining the mechanisms by which naturally occurring viral mutations influence the sensitivity of HIV-1 to bnAbs will provide information for the development of vaccines and bnAbs as anti-HIV-1 reagents.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  HIV-1; V2 apex bnAbs; infants; interprotomer interactions; rare mutation

Mesh:

Substances:

Year:  2020        PMID: 32669335      PMCID: PMC7495384          DOI: 10.1128/JVI.00814-20

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  55 in total

1.  A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding.

Authors:  C D Rizzuto; R Wyatt; N Hernández-Ramos; Y Sun; P D Kwong; W A Hendrickson; J Sodroski
Journal:  Science       Date:  1998-06-19       Impact factor: 47.728

2.  Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop.

Authors:  Penny L Moore; Elin S Gray; Daniel Sheward; Maphuti Madiga; Nthabeleng Ranchobe; Zhong Lai; William J Honnen; Molati Nonyane; Nancy Tumba; Tandile Hermanus; Sengeziwe Sibeko; Koleka Mlisana; Salim S Abdool Karim; Carolyn Williamson; Abraham Pinter; Lynn Morris
Journal:  J Virol       Date:  2011-01-26       Impact factor: 5.103

3.  Virus-like Particles Identify an HIV V1V2 Apex-Binding Neutralizing Antibody that Lacks a Protruding Loop.

Authors:  Evan M Cale; Jason Gorman; Nathan A Radakovich; Ema T Crooks; Keiko Osawa; Tommy Tong; Jiaqi Li; Raju Nagarajan; Gabriel Ozorowski; David R Ambrozak; Mangai Asokan; Robert T Bailer; Anthony K Bennici; Xuejun Chen; Nicole A Doria-Rose; Aliaksandr Druz; Yu Feng; M Gordon Joyce; Mark K Louder; Sijy O'Dell; Courtney Oliver; Marie Pancera; Mark Connors; Thomas J Hope; Thomas B Kepler; Richard T Wyatt; Andrew B Ward; Ivelin S Georgiev; Peter D Kwong; John R Mascola; James M Binley
Journal:  Immunity       Date:  2017-05-16       Impact factor: 31.745

4.  A smoothed backbone-dependent rotamer library for proteins derived from adaptive kernel density estimates and regressions.

Authors:  Maxim V Shapovalov; Roland L Dunbrack
Journal:  Structure       Date:  2011-06-08       Impact factor: 5.006

5.  The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection.

Authors:  Elin S Gray; Maphuti C Madiga; Tandile Hermanus; Penny L Moore; Constantinos Kurt Wibmer; Nancy L Tumba; Lise Werner; Koleka Mlisana; Sengeziwe Sibeko; Carolyn Williamson; Salim S Abdool Karim; Lynn Morris
Journal:  J Virol       Date:  2011-03-09       Impact factor: 5.103

6.  A generalized HIV vaccine design strategy for priming of broadly neutralizing antibody responses.

Authors:  Jon M Steichen; Ying-Cing Lin; Colin Havenar-Daughton; Simone Pecetta; Gabriel Ozorowski; Jordan R Willis; Laura Toy; Devin Sok; Alessia Liguori; Sven Kratochvil; Jonathan L Torres; Oleksandr Kalyuzhniy; Eleonora Melzi; Daniel W Kulp; Sebastian Raemisch; Xiaozhen Hu; Steffen M Bernard; Erik Georgeson; Nicole Phelps; Yumiko Adachi; Michael Kubitz; Elise Landais; Jeffrey Umotoy; Amanda Robinson; Bryan Briney; Ian A Wilson; Dennis R Burton; Andrew B Ward; Shane Crotty; Facundo D Batista; William R Schief
Journal:  Science       Date:  2019-10-31       Impact factor: 47.728

7.  Functional stability of unliganded envelope glycoprotein spikes among isolates of human immunodeficiency virus type 1 (HIV-1).

Authors:  Nitish Agrawal; Daniel P Leaman; Eric Rowcliffe; Heather Kinkead; Raman Nohria; Junya Akagi; Katherine Bauer; Sean X Du; Robert G Whalen; Dennis R Burton; Michael B Zwick
Journal:  PLoS One       Date:  2011-06-27       Impact factor: 3.240

8.  Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study.

Authors:  Yehuda Z Cohen; Allison L Butler; Katrina Millard; Maggi Witmer-Pack; Rebeka Levin; Cecilia Unson-O'Brien; Roshni Patel; Irina Shimeliovich; Julio C C Lorenzi; Jill Horowitz; Stephen R Walsh; Shu Lin; Joshua A Weiner; Anna Tse; Alicia Sato; Chelsey Bennett; Bryan Mayer; Kelly E Seaton; Nicole L Yates; Lindsey R Baden; Allan C deCamp; Margaret E Ackerman; Michael S Seaman; Georgia D Tomaras; Michel C Nussenzweig; Marina Caskey
Journal:  PLoS One       Date:  2019-08-08       Impact factor: 3.752

9.  Structural Constraints at the Trimer Apex Stabilize the HIV-1 Envelope in a Closed, Antibody-Protected Conformation.

Authors:  Christina Guzzo; Peng Zhang; Qingbo Liu; Alice L Kwon; Ferzan Uddin; Alexandra I Wells; Hana Schmeisser; Raffaello Cimbro; Jinghe Huang; Nicole Doria-Rose; Stephen D Schmidt; Michael A Dolan; Mark Connors; John R Mascola; Paolo Lusso
Journal:  mBio       Date:  2018-12-11       Impact factor: 7.867

10.  HIV-1 envelope glycoproteins isolated from Viremic Non-Progressor individuals are fully functional and cytopathic.

Authors:  Romina Cabrera-Rodríguez; Veronique Hebmann; Silvia Marfil; María Pernas; Sara Marrero-Hernández; Cecilia Cabrera; Victor Urrea; Concepción Casado; Isabel Olivares; Daniel Márquez-Arce; Silvia Pérez-Yanes; Judith Estévez-Herrera; Bonaventura Clotet; Lucile Espert; Cecilio López-Galíndez; Martine Biard-Piechaczyk; Agustín Valenzuela-Fernández; Julià Blanco
Journal:  Sci Rep       Date:  2019-04-03       Impact factor: 4.379

View more
  2 in total

1.  Regulation of epitope exposure in the gp41 membrane-proximal external region through interactions at the apex of HIV-1 Env.

Authors:  Hannah M Schapiro; Mukta D Khasnis; Koree Ahn; Alexandra Karagiaridi; Stephanie Hayden; Maria E Cilento; Michael J Root
Journal:  PLoS Pathog       Date:  2022-05-18       Impact factor: 7.464

2.  Global Increases in Human Immunodeficiency Virus Neutralization Sensitivity Due to Alterations in the Membrane-Proximal External Region of the Envelope Glycoprotein Can Be Minimized by Distant State 1-Stabilizing Changes.

Authors:  Qian Wang; Florian Esnault; Meiqing Zhao; Ta-Jung Chiu; Amos B Smith; Hanh T Nguyen; Joseph G Sodroski
Journal:  J Virol       Date:  2022-03-15       Impact factor: 6.549

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.